Transcript Slide 1
<br />CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma of the colon or rectum <br /> Presented By Alan Venook at 2014 ASCO Annual Meeting Slide 2 Presented By Alan Venook at 2014 ASCO Annual Meeting CALGB/SWOG 80405: <br /> FINAL DESIGN Presented By Alan Venook at 2014 ASCO Annual Meeting COLORECTAL CANCER IN 2004 <br /> IS THERE AN OPTIMAL 1ST LINE TREATMENT ? Presented By Alan Venook at 2014 ASCO Annual Meeting 2004: A lot can happen in 10 years Presented By Alan Venook at 2014 ASCO Annual Meeting CALGB / SWOG 80405: <br /> WHY DID IT TAKE TEN YEARS? Presented By Alan Venook at 2014 ASCO Annual Meeting CALGB/SWOG 80405: Eligibility Criteria Presented By Alan Venook at 2014 ASCO Annual Meeting CALGB/SWOG 80405: Endpoints Presented By Alan Venook at 2014 ASCO Annual Meeting CALGB/SWOG 80405: Statistics Presented By Alan Venook at 2014 ASCO Annual Meeting CALGB/SWOG 80405: Statistics Presented By Alan Venook at 2014 ASCO Annual Meeting Slide 11 Presented By Alan Venook at 2014 ASCO Annual Meeting Slide 12 Presented By Alan Venook at 2014 ASCO Annual Meeting CALGB/SWOG 80405: Overall Survival <br /> Presented By Alan Venook at 2014 ASCO Annual Meeting CALGB/SWOG 80405: Progression-Free Survival<br />(Investigator Determined) Presented By Alan Venook at 2014 ASCO Annual Meeting Slide 15 Presented By Alan Venook at 2014 ASCO Annual Meeting CALGB/SWOG 80405: Overall Survival<br />FOLFOX Treated Presented By Alan Venook at 2014 ASCO Annual Meeting CALGB/SWOG 80405: Overall Survival<br />FOLFIRI Treated Presented By Alan Venook at 2014 ASCO Annual Meeting Patients Rendered Disease-Free<br />Overall Survival Presented By Alan Venook at 2014 ASCO Annual Meeting Grade 3-4 Toxicities<br /> Presented By Alan Venook at 2014 ASCO Annual Meeting Slide 20 Presented By Alan Venook at 2014 ASCO Annual Meeting 80405: Data Pending Presented By Alan Venook at 2014 ASCO Annual Meeting Quality of Life and Symptoms Presented By Alan Venook at 2014 ASCO Annual Meeting Slide 23 Presented By Alan Venook at 2014 ASCO Annual Meeting “Expanded RAS” Presented By Alan Venook at 2014 ASCO Annual Meeting <br /> Correlative Studies<br /> Tumor / Plasma / Serum > 44000 samples<br /> Presented By Alan Venook at 2014 ASCO Annual Meeting 80405: Upcoming Presentations Presented By Alan Venook at 2014 ASCO Annual Meeting CALGB/SWOG 80405: Conclusions Presented By Alan Venook at 2014 ASCO Annual Meeting CALGB/SWOG 80405: Conclusions Presented By Alan Venook at 2014 ASCO Annual Meeting CALGB/SWOG 80405: Conclusions Presented By Alan Venook at 2014 ASCO Annual Meeting Slide 30 Presented By Alan Venook at 2014 ASCO Annual Meeting TAKE HOME MESSAGE Presented By Alan Venook at 2014 ASCO Annual Meeting Value of publicly funded clinical research Presented By Alan Venook at 2014 ASCO Annual Meeting ACKNOWLEDGEMENTS / THANKS Collaborators Presented By Alan Venook at 2014 ASCO Annual Meeting ACKNOWLEDGEMENT / THANK YOU Presented By Alan Venook at 2014 ASCO Annual Meeting Slide 35 Presented By Alan Venook at 2014 ASCO Annual Meeting Slide 36 Presented By Alan Venook at 2014 ASCO Annual Meeting